About Index Trending news
Lists
Pricing
Resverlogix Corp.

Resverlogix Corp.

Resverlogix Corp.

RVX-208 is a first-in-class, selective BET bromodomain inhibitor treating patients with cardiovascular disease, diabetes mellitus, and other serious diseases.

Elsewhere

Contributors to this profile

Alexa global traffic share

Twitter followers

Latest funding Show all
Post-IPO equity
$10,000,000
Eastern Capital, Shenzhen Hepalink Pharmaceutical Co Ltd
Post-IPO debt
$30,000,000
Employees

Team size

10+
Locations
HQ
Headquarters
$10,000,000 Post-IPO equity
PE Hub

Eastern, Hepalink invest in Resverlogix's $10 mln offering

Stock markets Privacy Health